Fibromyalgia antibodies

and ELISA kits, proteins related to Fibromyalgia.

Introduction to Fibromyalgia

Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Affecting millions worldwide, it significantly impacts daily life, limiting physical activities and reducing overall quality of life. Despite its prevalence, the exact cause of fibromyalgia remains elusive, making diagnosis and treatment challenging. Recent advancements in medical research have begun to shed light on the underlying mechanisms, with a particular focus on the role of the immune system. Investigating specific antibodies related to fibromyalgia holds promise for developing more effective diagnostics and targeted therapies. Understanding these antibody interactions may unlock new pathways to alleviate symptoms and improve outcomes for those living with this debilitating condition. Our commitment to advancing fibromyalgia research aims to transform the lives of patients through innovative scientific discovery and compassionate care.

Fibromyalgia biomarkers

PA1239

Anti-GFAP Antibody Picoband®, BSHX decoction reduced reactive astrocytosis after SCI. A Immunofluorescence images showed the reactive astrocytosis (GFAP, red) at day 3 and 7 after SCI. B Immuno...

MA1045

Anti-GFAP Antibody (Monoclonal, G-A-5), IF analysis of GFAP using anti-GFAP antibody (MA1045) .
GFAP was detected in an immunocytochemical section of rat C6 cells. The cells were f...

PB9449

Anti-Tyrosine Hydroxylase/TH Antibody Picoband®, IF analysis of Tyrosine Hydroxylase/TH using anti-Tyrosine Hydroxylase/TH antibody (PB9449).
Tyrosine Hydr...

Protein Name	Gene Name	Function
Brain-Derived Neurotrophic Factor	BDNF	Supports neuron growth and synaptic plasticity, linked to pain sensitivity.
Substance P	TAC1	Neuropeptide involved in transmitting pain signals.
Catechol-O-Methyltransferase	COMT	Enzyme that breaks down catecholamines, affecting pain sensitivity.
Interleukin-6	IL6	Pro-inflammatory cytokine involved in immune response.
Tumor Necrosis Factor-alpha	TNF	Pro-inflammatory cytokine contributing to inflammation.
C-Reactive Protein	CRP	Marker of systemic inflammation.
Dopamine	TH	Neurotransmitter involved in mood regulation and pain.
Serotonin Transporter	SLC6A4	Regulates serotonin levels in the synaptic cleft.
Neuropeptide Y	NPY	Involved in stress response and modulation of pain.
Fibroblast Growth Factor 2	FGF2	Promotes nerve repair and maintenance.
Glial Fibrillary Acidic Protein	GFAP	Marker for astroglial activation and neuroinflammation.
Melatonin	AANAT	Regulates sleep cycles and has analgesic properties.
Galanin	GAL	Neuropeptide involved in pain modulation and mood regulation.
Chemokine Receptor 4	CCR4	Involved in immune cell migration and inflammatory responses.
Vasoactive Intestinal Peptide	VIP	Modulates vasodilation and pain perception.
α2-Adrenergic Receptor	ADRA2A	Receptor involved in norepinephrine-mediated pain modulation.
Substance P Receptor	TACR1	Receptor for Substance P, key in pain signal transmission.
Interleukin-8	CXCL8	Chemokine involved in the recruitment of immune cells during inflammation.

Important Mechanisms

Central Sensitization

Central sensitization is a fundamental mechanism in the pathophysiology of fibromyalgia, characterized by an increased responsiveness of neurons in the central nervous system to normal or subthreshold sensory inputs. This heightened sensitivity results in the amplification of pain signals, making individuals more susceptible to experiencing pain from stimuli that are typically non-painful, a phenomenon known as allodynia. Additionally, central sensitization contributes to hyperalgesia, where the perception of pain is exaggerated. The underlying processes involve alterations in neurotransmitter levels, such as increased glutamate and decreased GABAergic inhibition, which facilitate the persistent activation of pain pathways. Moreover, structural and functional changes in brain regions responsible for pain processing, including the anterior cingulate cortex and insula, have been observed in fibromyalgia patients. Understanding central sensitization is crucial as it not only elucidates the persistent and widespread pain characteristic of fibromyalgia but also guides the development of targeted treatments. Therapeutic approaches aimed at modulating central nervous system excitability, such as certain pharmacological agents and cognitive-behavioral therapies, hold promise in alleviating the heightened pain sensitivity associated with this condition.

Neuroinflammation

Neuroinflammation has emerged as a significant area of research in understanding fibromyalgia, highlighting the role of inflammatory processes within the central nervous system in the development and maintenance of chronic pain. Unlike peripheral inflammation, neuroinflammation involves the activation of glial cells, such as microglia and astrocytes, which release pro-inflammatory cytokines and chemokines. These inflammatory mediators can enhance neuronal excitability and synaptic transmission, thereby exacerbating pain perception. Studies using advanced imaging techniques have identified increased markers of neuroinflammation in key pain-processing areas of the brain in fibromyalgia patients. Furthermore, neuroinflammation may interact with other pathophysiological mechanisms, including central sensitization and autonomic dysfunction, creating a complex network that sustains chronic pain and other symptoms like fatigue and cognitive disturbances. Investigating neuroinflammation not only provides deeper insights into the biological underpinnings of fibromyalgia but also opens avenues for novel therapeutic interventions. Anti-inflammatory agents, glial cell modulators, and strategies to reduce pro-inflammatory cytokine production are being explored as potential treatments to mitigate the neuroinflammatory component of fibromyalgia, offering hope for more effective symptom management.